MARKET NEWS

 

Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative & Biothreat Pathogens
Atea’s Oral Antiviral Drug Candidate Reduces Viral Replication in Hospitalized Patients With COVID-19 in Phase 2 Interim Analysis
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients With Chronic Rhinosinusitis
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process Method Does Not Require Antibody Conjugated Metallic Nanoparticles
OSE Immunotherapeutics Announces Manufacturing Agreement With Cenexi 
Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

Eurofins BioPharma Product Testing offers complete CMC Testing Services for the Bio/Pharmaceutical industry, including all starting materials, process intermediates, drug substances, drug product, packaging, and manufacturing support through our broad technical expertise in Biochemistry, Molecular & Cell Biology, Virology, Chemistry and Microbiology. With a global capacity of more than 1,720,000 square feet of facilities and 36 locations worldwide, our network of GMP laboratories and vast experience allow us to support projects of any size from conception to market. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Brickell Biotech Announces Final Patient Completed in First US Phase 3 Pivotal Clinical Study & Patient Enrollment Completed in Second US Phase 3 Pivotal Clinical Study

Brickell Biotech Announces Final Patient Completed in First US Phase 3 Pivotal Clinical Study & Patient Enrollment Completed in Second US Phase 3 Pivotal Clinical Study

Brickell Biotech, Inc. recently announced the final patient has completed the Phase 3 pivotal Cardigan I study, and that all planned patients have been enrolled in the Phase 3 pivotal Cardigan II study…..

BioAegis Awarded BARDA Contract to Advance Development of a Novel Host-Directed Human Protein for Patients With Sepsis & Severe Infection

BioAegis Awarded BARDA Contract to Advance Development of a Novel Host-Directed Human Protein for Patients With Sepsis & Severe Infection

BioAegis Therapeutics Inc. recently announced it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, to further….

Apellis & Beam Therapeutics Enter Exclusive Research Collaboration

Apellis & Beam Therapeutics Enter Exclusive Research Collaboration

Apellis Pharmaceuticals, Inc. and Beam Therapeutics Inc. recently announced an exclusive 5-year research collaboration focused on the use of Beam’s proprietary base editing technology to discover new….

Encoded Therapeutics Partners With Genedata to Accelerate AAV-Based Gene Therapy Development 

Encoded Therapeutics Partners With Genedata to Accelerate AAV-Based Gene Therapy Development 

Genedata recently announced that Encoded Therapeutics has chosen Genedata Bioprocess to digitalize their proprietary gene therapy R&D technology…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 4 – Controlled Release
August 11 – Analytical Testing